Clinical trials: Polypoidal Choroidal Vasculopathy
Age Related Macular Degeneration
PDT Study for Exudative AMD With PCV
The purpose of this study is to evaluate and conduct an exploratory comparison of the efficacy and safety of indocyanine green angiography (ICGA) guided photodynamic therapy (PDT) and fluorescein angiography (FA) guided PDT for…
- Trial name
- NCT00331435
- Testing
- Ocular photodynamic therapy with verteporfin
- Where
- 17 sites in Japan
- Volunteers
- 113 people
- Sponsor
- Ophthalmic PDT Study Group
Polypoidal Choroidal Vasculopathy
Double-dose Ranibizumab for Polypoidal Choroidal Vasculopathy
The purpose of this study is to determine whether double-dose Ranibizumab are effective to regress the polyps and benefit to the visual outcome in the polypoidal choroidal vasculopathy (PCV).
- Trial name
- NCT02769169
- Testing
- Lucentis® (Raibizumab) double-dose, Lucentis® (Raibizumab) regular-dose
- Where
- 4 sites in China
- Volunteers
- 5 people
- Sponsor
- Sun Yat-sen University
Choroidal Neovascularization, Choroid Disease
Treatment of Polypoidal Choroidal Vasculopathy in Pachychoroid
This study will evaluate patients with diagnosis of polypoidal choroidal vasculopathy (PCV) in pachychoroid treated with combined therapy, consisting in photodynamic therapy (PDT) and 3 intravitreal therapy (IVT) of Aflibercept…
- Trial name
- NCT04075188
- Testing
- Aflibercept Injection
- Where
- Italy
- Volunteers
- 17 people
- Sponsor
- Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo
Polypoidal Choroidal Vasculopathy
Clinical Implication of Aflibercept in PCV Treatment in China
The purpose of this study is to evaluate the overall treatment characteristics and efficacy of Aflibercept in the treatment of PCV in China through a multicenter, observational, prospective-retrospective study.
- Trial name
- NCT05639660
- Testing
- non-interventional
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Peking Union Medical College Hospital
Macular Polypoidal Choroidal Vasculopathy (PCV)
Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy
This study is a 60-week, two-arm, randomized, open-label, active-controlled, multi-center study in patients with Polypoidal choroidal vasculopathy (PCV) who have not previously received anti-Vascular endothelial growth factor…
- Trial name
- PROUD (NCT05666804)
- Testing
- Brolucizumab 6mg
- Where
- 15 sites in South Korea
- Volunteers
- 148 people
- Sponsor
- Novartis Pharmaceuticals
Polypoidal Choroidal Vasculopathy
Study to Investigate the Efficacy, Safety and Durability of Faricimab in Caucasian Patients With Polypoidal Choroidal Vasculopathy (MONDEGO)
The goal of this clinical trial is to assess the efficacy, safety and durability of faricimab in caucasian patients with polypoidal choroidal vasculopathy (PCV).
- Trial name
- MONDEGO (NCT06709339)
- Testing
- Faricimab Injection [Vabysmo]
- Where
- 31 sites in Italy, Portugal and 2 more
- Volunteers
- 120 people
- Sponsor
- Association for Innovation and Biomedical Research on Light and Image
Age-related Macular Degeneration
Eyes That Do Not Meet the Eligibility Criteria of Clinical Trials on Age-Related Macular Degeneration: Proportion of the Real-World Patient Population and Reasons for Exclusion
The purpose of the present study was to evaluate the proportion of eyes that do not meet the eligibility criteria of clinical trials on neovascular AMD among the entire sample of eyes diagnosed with treatment-naïve neovascular…
- Trial name
- NCT04836143
- Testing
- Intravitreal anti-vascular endothelial growth factor injection
- Where
- South Korea
- Volunteers
- 512 people
- Sponsor
- Kim's Eye Hospital
Exudative Age-related Macular Degeneration, Polypoidal Choroidal Vasculopathy
Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy
Changes of intraocular cytokines including vascular endothelial growth factor (VEGF) will be measured in recurrence of polypoidal choroidal vasculopathy (PCV) during treatment of ranibizumab.
- Trial name
- CyPov (NCT02976194)
- Testing
- ranibizumab
- Where
- 2 sites in South Korea
- Volunteers
- 28 people
- Sponsor
- Pusan National University Hospital
Polypoidal Choroidal Vasculopathy, Conbercept
Conbercept for Polypoidal Choroidal Vasculopathy（START Study）
1. To evaluate the effectiveness of Conbercept for PCV patients. 2. To describe the characteristics of PCV. 3. To describe the adverse events (AE) of Conbercept in the treatment of PCV. 4.
- Trial name
- NCT05229237
- Testing
- Conbercept
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Peking Union Medical College Hospital
Polypoidal Choroidal Vasculopathy
Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy
1. Primary objectives a. To evaluate the Effects of intravitreal Bevacizumab on polypoidal choroidal vasculopathy(PCV) 2. Secondary objectives 1. To assess the changes in visual acuity 2.
- Trial name
- NCT00383812
- Testing
- Intravitreal Bevacizumab
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Asan Medical Center
Polypoidal Choroidal Vasculopathy
Interval of Disease Inactivity After Complete Polypoidal Regression in PCV Receiving Aflibercept
Polypoidal choroidal vasculopathy (PCV), a subtype of neovascular age-related macular degeneration (NV AMD), is an important cause of central visual loss, especially among Asian and African descendants.
- Trial name
- NCT04707027
- Testing
- Aflibercept Injection (2 mg/0.05 ml), Defer treatment
- Where
- Thailand
- Volunteers
- 80 people
- Sponsor
- Chiang Mai University
Polypoidal Choroidal Vasculopathy
Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy
This Phase I/II study will investigate the safety and tolerability of intravitreally administered 0.5mg and 1.0 or 2.0mg Ranibizumab in three monthly doses followed by a 9 month period of criteria-based, as-needed retreatment and…
- Trial name
- NCT01469156
- Testing
- ranibizumab 0.5 or 2.0 mg/0.05 cc
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Southeast Retina Center, Georgia
Polypoidal Choroidal Vasculopathy
Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV)
This is a 12 month study of monthly injections of ranibizumab in subjects with polypoidal choroidal vasculopathy as diagnosed by fluoresceins/indocyanine green (FA/ICG) angiography.
- Trial name
- PEARL (NCT00424710)
- Testing
- ranibizumab intravitreal injection
- Where
- 2 sites in United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Hawaii Pacific Health
Polypoidal Choroidal Vasculopathy
Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy
This study aims to compare the efficacy of ranibizumab and verteporfin PDT combination treatment and verteporfin PDT monotherapy vs.ranibizumab monotherapy alone in achieving complete regression of polyps in patients with…
- Trial name
- PCV (NCT00674323)
- Testing
- Verteporfin Photodynamic Therapy, Ranibizumab
- Where
- 5 sites in Hong Kong, Singapore and 3 more
- Volunteers
- 61 people
- Sponsor
- Novartis
Symtomatic Macular Polypoidal Choroidal Vasculopathy
Intravitreal Aflibercept for Treatment of Polypoidal Choroidal Vasculopathy (PCV)
Objective: To evaluate the efficacy of intravitreal aflibercept injection on visual acuity in patients with symptomatic macular PCV.
- Trial name
- NCT02860858
- Testing
- Intravitreous aflibercept injection
- Where
- Thailand
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Department of Medical Services Ministry of Public Health of Thailand
Polypoidal Choroidal Vasculopathy
Efficacy and Safety of Two Regimens of Anti-VEGF Therapy in Chinese Patients With Polypoidal Choroidal Vasculopathy
The study will evaluate the efficacy and safety of two different regimens of anti-VEGF Therapy (OCTA plus OCT guided 3+PRN vs. OCT guided 3+PRN) in Chinese patients with PCV.
- Trial name
- NCT04380974
- Testing
- OCTA plus OCT guided 3+PRN regimen, OCT guided 3+PRN regimen, Anti-VEGF drug
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Xiaodong Sun
Age-Related Macular Degeneration
Vascular Endothelial Growth Factor (VEGF) & LOC387715/HTRA1 Polymorphism in Polypoidal Choroidal Vasculopathy
This study is to investigate whether there is an association of the LOC387715/HTRA1 and vascular endothelial growth factor polymorphism with response to treatment with intravitreal ranibizumab injections for patients with…
- Trial name
- NCT01233128
- Where
- South Korea
- Volunteers
- 121 people
- Sponsor
- Kyungpook National University Hospital
Polypoidal Chorodial Vasculopathy, Age Related Macular Degeneration
IRay to Treat Polypoidal Choroidal Vasculopathy (PCV) Secondary to Age-Related Macular Degeneration (AMD
This study will evaluate the efficacy of IRay treatment in patients with Polypoidal Choroidal Vasculopathy (PCV)secondary to AMD as determined by the change in the proportion of lesion activity and lesion size at 12 months.
- Trial name
- NCT01516294
- Testing
- Iray
- Where
- Italy
- Volunteers
- 12 people
- Sponsor
- Oraya Therapeutics, Inc.
Age-Related Macular Degeneration, Polypoidal Choroidal Vasculopathy
Pharmacogenomic Study on Anti-VEGF Medicine in Treatment of Macular Neovascular Diseases
Macular neovascular diseases including age-related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV), pathological myopia (PM) and etc. can cause severe vision loss.
- Conditions
- Age-Related Macular Degeneration, Polypoidal Choroidal Vasculopathy, Pathological Myopia, Conbercept
- Trial name
- NCT03128463
- Testing
- Intravitreal injection of conbercept
- Where
- China
- Volunteers
- 5,000 people
- Sponsor
- Xun Xu
Neovascular Age-Related Macular Degeneration
Intense Treatment Regimen With Intravitreal Aflibercept Injection
This study will evaluate the safety and efficacy of intense dosing for a limited period in patients who demonstrate refractory disease on monthly IAI. Patients will be followed for 52 weeks
- Trial name
- I-TRAP (NCT03594461)
- Testing
- Aflibercept Injection
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Vitreous -Retina- Macula Consultants of New York